TAM
CHRS icon

Tiverton Asset Management’s Coherus Oncology CHRS Stock Holding History

Tiverton Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$90K Hold
4,459
– – ﹤0.01% 652
2019
Q2 		$99K Hold
4,459
– – ﹤0.01% 624
2019
Q1 		$61K Buy
4,459
+1,053
+31% +$14K ﹤0.01% 621
2018
Q4 		$31K Buy
+3,406
New +$39.4K ﹤0.01% 472

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Tiverton Asset Management's CHRS Position: Q3 2019 in Review

Tiverton Asset Management held its Coherus Oncology (CHRS) position steady in Q3 2019 at 4,459 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #652.

Tiverton Asset Management first reported a position in CHRS in Q4 2018 and has held it in 4 quarters since. The position peaked at $99K in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Tiverton Asset Management held 4,459 shares of Coherus Oncology worth $90K as of Q3 2019.
  • Tiverton Asset Management left its Coherus Oncology share count unchanged in Q3 2019.
  • Coherus Oncology made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #652 holding.
  • Tiverton Asset Management first reported a position in Coherus Oncology in Q4 2018 and has held it in 4 quarters since.
  • Tiverton Asset Management's Coherus Oncology position peaked at $99K in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.